hyperbaric bupivacaine and dexmedetomidine
ApprovedSmall molecule
hyperbaric bupivacaine and dexmedetomidine is one of 23 small molecule programs targeting Urinary retention. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Urinary Retention
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Robinul
Alnylam PharmaceuticalsApproved
Avodart
Akero TherapeuticsApproved
Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Ivadantin
PProcter and Gamble
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Uroxatral
AAdvanz Pharma
Phase 3
Tamsulosin OCAS
AstellasPhase 3
Zanaflex
LLegacy Health System
Phase 3
Azo-Standard
UUniversity of Massachusetts, Worcester
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- LLady Reading Hospital, Pakistan